These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 11739444

  • 21. Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate.
    Fulcher GR, Walker M, Farrer M, Johnson AS, Alberti KG.
    Metabolism; 1993 Mar; 42(3):308-14. PubMed ID: 8487648
    [Abstract] [Full Text] [Related]

  • 22. Combination therapy with acipimox enhances the effect of growth hormone treatment on linear body growth in the normal and small-for-gestational-age rat.
    Vickers MH, Hofman PL, Gluckman PD, Lobie PE, Cutfield WS.
    Am J Physiol Endocrinol Metab; 2006 Dec; 291(6):E1212-9. PubMed ID: 16803850
    [Abstract] [Full Text] [Related]

  • 23. Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
    Vaag A, Skött P, Damsbo P, Gall MA, Richter EA, Beck-Nielsen H.
    J Clin Invest; 1991 Oct; 88(4):1282-90. PubMed ID: 1918378
    [Abstract] [Full Text] [Related]

  • 24. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients.
    Bajaj M, Suraamornkul S, Romanelli A, Cline GW, Mandarino LJ, Shulman GI, DeFronzo RA.
    Diabetes; 2005 Nov; 54(11):3148-53. PubMed ID: 16249438
    [Abstract] [Full Text] [Related]

  • 25. Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle.
    Bramnert M, Segerlantz M, Laurila E, Daugaard JR, Manhem P, Groop L.
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1455-63. PubMed ID: 12679422
    [Abstract] [Full Text] [Related]

  • 26. Effects of morning cortisol replacement on glucose and lipid metabolism in GH-treated subjects.
    Segerlantz M, Bramnert M, Thomasson R, Manhem P, Laurila E, Groop LC.
    Eur J Endocrinol; 2004 Dec; 151(6):701-7. PubMed ID: 15588236
    [Abstract] [Full Text] [Related]

  • 27. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.
    Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ, Strassmann PG, Wajchenberg BL.
    Diabetes; 1999 Sep; 48(9):1836-41. PubMed ID: 10480616
    [Abstract] [Full Text] [Related]

  • 28. Acute pharmacologic blockade of lipolysis normalizes nocturnal growth hormone levels and pulsatility in obese subjects.
    Andreotti AC, Lanzi R, Manzoni MF, Caumo A, Moreschi A, Pontiroli AE.
    Metabolism; 1994 Oct; 43(10):1207-13. PubMed ID: 7934970
    [Abstract] [Full Text] [Related]

  • 29. Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects.
    Lanzi R, Luzi L, Caumo A, Andreotti AC, Manzoni MF, Malighetti ME, Sereni LP, Pontiroli AE.
    Metabolism; 1999 Sep; 48(9):1152-6. PubMed ID: 10484056
    [Abstract] [Full Text] [Related]

  • 30. Mechanisms of dexamethasone-induced insulin resistance in healthy humans.
    Tappy L, Randin D, Vollenweider P, Vollenweider L, Paquot N, Scherrer U, Schneiter P, Nicod P, Jéquier E.
    J Clin Endocrinol Metab; 1994 Oct; 79(4):1063-9. PubMed ID: 7962275
    [Abstract] [Full Text] [Related]

  • 31. Insulin resistance induced by growth hormone is linked to lipolysis and associated with suppressed pyruvate dehydrogenase activity in skeletal muscle: a 2 × 2 factorial, randomised, crossover study in human individuals.
    Hjelholt AJ, Charidemou E, Griffin JL, Pedersen SB, Gudiksen A, Pilegaard H, Jessen N, Møller N, Jørgensen JOL.
    Diabetologia; 2020 Dec; 63(12):2641-2653. PubMed ID: 32945898
    [Abstract] [Full Text] [Related]

  • 32. Inhibition of lipolysis stimulates peripheral glucose uptake but has no effect on endogenous glucose production in HIV lipodystrophy.
    Lindegaard B, Frøsig C, Petersen AM, Plomgaard P, Ditlevsen S, Mittendorfer B, Van Hall G, Wojtaszewski JF, Pedersen BK.
    Diabetes; 2007 Aug; 56(8):2070-7. PubMed ID: 17601993
    [Abstract] [Full Text] [Related]

  • 33. Inhibition of lipolysis stimulates whole body glucose production and disposal in normal postabsorptive subjects.
    Fery F, Plat L, Baleriaux M, Balasse EO.
    J Clin Endocrinol Metab; 1997 Mar; 82(3):825-30. PubMed ID: 9062490
    [Abstract] [Full Text] [Related]

  • 34. Plasma free fatty acids and serum insulin in subjects feeding at 12-hour intervals; effects of methionyl growth hormone and of acipimox, an inhibitor of lipolysis.
    Pontiroli AE, Lanzi R, Monzani M, Musatti L, Guglielmone C, Pozza G.
    J Endocrinol Invest; 1992 Feb; 15(2):85-91. PubMed ID: 1569294
    [Abstract] [Full Text] [Related]

  • 35. Lowering plasma free fatty acids with Acipimox mimics the antidiabetic effects of the beta 3-adrenergic agonist CL-316243 in obese Zucker diabetic fatty rats.
    Blachère JC, Pérusse F, Bukowiecki LJ.
    Metabolism; 2001 Aug; 50(8):945-51. PubMed ID: 11474483
    [Abstract] [Full Text] [Related]

  • 36. Dose-response effects of free fatty acids on glucose and lipid metabolism during somatostatin blockade of growth hormone and insulin in humans.
    Gormsen LC, Jessen N, Gjedsted J, Gjedde S, Nørrelund H, Lund S, Christiansen JS, Nielsen S, Schmitz O, Møller N.
    J Clin Endocrinol Metab; 2007 May; 92(5):1834-42. PubMed ID: 17341555
    [Abstract] [Full Text] [Related]

  • 37. Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis.
    Lucidi P, Rossetti P, Porcellati F, Pampanelli S, Candeloro P, Andreoli AM, Perriello G, Bolli GB, Fanelli CG.
    Diabetes; 2010 Jun; 59(6):1349-57. PubMed ID: 20299466
    [Abstract] [Full Text] [Related]

  • 38. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
    Lee EJ, Nam SY, Kim KR, Lee HC, Cho JH, Nam MS, Song YD, Lim SK, Huh KB.
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
    [Abstract] [Full Text] [Related]

  • 39. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.
    Bajaj M, Suraamornkul S, Kashyap S, Cusi K, Mandarino L, DeFronzo RA.
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4649-55. PubMed ID: 15356076
    [Abstract] [Full Text] [Related]

  • 40. Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans.
    Hussain MA, Schmitz O, Mengel A, Glatz Y, Christiansen JS, Zapf J, Froesch ER.
    J Clin Invest; 1994 Sep; 94(3):1126-33. PubMed ID: 8083353
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.